The MHRA, Advertising Standards Authority, and the General Pharmaceutical Council have collectively issued a warning to businesses regarding the promotion of newly authorized prescription-only medicines and unlicensed medicines intended for weight management. This advisory comes in light of increasing concerns about the potential for misleading marketing practices that could undermine patient safety and regulatory compliance.
In recent years, the weight management sector has seen a surge in interest, prompting companies to aggressively market both newly licensed and unlicensed products. However, the regulatory bodies emphasize that promoting such medicines without appropriate marketing authorization poses significant risks, including the potential for misinformation and adverse health outcomes.
As a result, stakeholders in the pharmaceutical industry, particularly those involved in regulatory affairs, quality assurance, and commercial strategy, must exercise heightened vigilance. This warning serves as a crucial reminder of the importance of adhering to established guidelines to maintain industry integrity and protect public health.
Use the database as your supply chain compass →
